Skip to main content
S 1078 115th Congress Senate Health Congressional oversight Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug trafficking and controlled substances Federal officials Food and Drug Administration (FDA) Government ethics and transparency, public corruption Marketing and advertising Prescription drugs

FDA Accountability for Public Safety Act

Introduced: May 9, 2017 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 9, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 9, 2017
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

FDA Accountability for Public Safety Act

This bill amends the Comprehensive Addiction and Recovery Act of 2016 to expand the scope of the Food and Drug Administration (FDA) advisory committee to make recommendations regarding supplemental applications for opioids. Currently, the committee only makes recommendations on new drug applications.

Only the Commissioner of Food and Drugs may approve a new drug application or supplement to an application for an opioid against the recommendation of the committee. If the Commissioner approves a drug against the recommendation of the committee, the Commissioner must: (1) submit a report to Congress that includes the evidence regarding patient safety that supports the Commissioner's decision and a disclosure of any potential conflicts of interest of FDA officials involved in the decision; and (2) testify before Congress regarding the decision, upon request. Such a drug cannot be sold until the Commissioner has submitted the report.

What's happening now May 9, 2017

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 2
All 2 Republican 1 Independent 1
R
Capito, Shelley Moore
West Virginia · May 9, 2017
 I
King, Angus S., Jr.
Maine · May 9, 2017
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1078: FDA Accountability for Public Safety Act. 115th Congress. Open America. https://openamerica.io/bill/115-S-1078/
MLA
"S. 1078: FDA Accountability for Public Safety Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-1078/.
Bluebook (legal)
S. 1078, 115th Cong. (2026), https://openamerica.io/bill/115-S-1078/.
Markdown link
[S. 1078: FDA Accountability for Public Safety Act](https://openamerica.io/bill/115-S-1078/)
Report a problem